U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Untreated Extensive Stage Small Cell Lung Carcinoma

MedGen UID:
1381539
•Concept ID:
C4331482
•
Finding

Definition

A finding of small cell carcinoma which has spread beyond one hemi-thorax and the regional lymph nodes and has not been treated. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUntreated Extensive Stage Small Cell Lung Carcinoma

Professional guidelines

PubMed

Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer.
Rittberg R, Banerji S, Kim JO, Rathod S, Dawe DE
Am J Clin Oncol 2021 Dec 1;44(12):629-638. doi: 10.1097/COC.0000000000000867. PMID: 34628433
Outcome of treatment in patients with small cell lung cancer in poor performance status.
Bahij R, Jeppesen SS, Olsen KE, Halekoh U, Holmskov K, Hansen O
Acta Oncol 2019 Nov;58(11):1612-1617. Epub 2019 Jul 8 doi: 10.1080/0284186X.2019.1637934. PMID: 31282251
Differential diagnosis of small cell neuroendocrine carcinoma of the lung.
Warren WH, Gould VE
Chest Surg Clin N Am 1997 Feb;7(1):49-63. PMID: 9001755

Recent clinical studies

Etiology

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, Shi J, Wang X, Bai Y, Melkadze T, Pan Y, Min X, Viguro M, Li X, Zhao Y, Yang J, Makharadze T, Arkania E, Kang W, Wang Q, Zhu J; ASTRUM-005 Study Group
JAMA 2022 Sep 27;328(12):1223-1232. doi: 10.1001/jama.2022.16464. PMID: 36166026Free PMC Article
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group
Lancet Oncol 2022 Jun;23(6):739-747. Epub 2022 May 13 doi: 10.1016/S1470-2045(22)00224-8. PMID: 35576956
Durvalumab: A Review in Extensive-Stage SCLC.
Al-Salama ZT
Target Oncol 2021 Nov;16(6):857-864. Epub 2021 Nov 3 doi: 10.1007/s11523-021-00843-0. PMID: 34731446Free PMC Article
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR; KEYNOTE-604 Investigators
J Clin Oncol 2020 Jul 20;38(21):2369-2379. Epub 2020 May 29 doi: 10.1200/JCO.20.00793. PMID: 32468956Free PMC Article
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators
Lancet 2019 Nov 23;394(10212):1929-1939. Epub 2019 Oct 4 doi: 10.1016/S0140-6736(19)32222-6. PMID: 31590988

Diagnosis

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Bria E, Morgillo F, Garassino MC, Ciardiello F, Ardizzoni A, Stefani A, Verderame F, Morabito A, Chella A, Tonini G, Gilli M, Del Signore E, Berardi R, Mencoboni M, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Pazzola A, Iero M, De Marinis F
Oncologist 2024 May 3;29(5):e690-e698. doi: 10.1093/oncolo/oyad342. PMID: 38377176Free PMC Article
First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Lin S, Luo S, Gu D, Li M, Rao X, Wang C, Huang P, Xu X, Weng X
Oncologist 2021 Nov;26(11):e2013-e2020. Epub 2021 Sep 12 doi: 10.1002/onco.13954. PMID: 34431578Free PMC Article
Outcome of treatment in patients with small cell lung cancer in poor performance status.
Bahij R, Jeppesen SS, Olsen KE, Halekoh U, Holmskov K, Hansen O
Acta Oncol 2019 Nov;58(11):1612-1617. Epub 2019 Jul 8 doi: 10.1080/0284186X.2019.1637934. PMID: 31282251
Small cell lung cancer: state-of-the-art therapy in 1996.
Elias AD
Chest 1997 Oct;112(4 Suppl):251S-258S. doi: 10.1378/chest.112.4_supplement.251s. PMID: 9337299
Differential diagnosis of small cell neuroendocrine carcinoma of the lung.
Warren WH, Gould VE
Chest Surg Clin N Am 1997 Feb;7(1):49-63. PMID: 9001755

Therapy

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, Shi J, Wang X, Bai Y, Melkadze T, Pan Y, Min X, Viguro M, Li X, Zhao Y, Yang J, Makharadze T, Arkania E, Kang W, Wang Q, Zhu J; ASTRUM-005 Study Group
JAMA 2022 Sep 27;328(12):1223-1232. doi: 10.1001/jama.2022.16464. PMID: 36166026Free PMC Article
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group
Lancet Oncol 2022 Jun;23(6):739-747. Epub 2022 May 13 doi: 10.1016/S1470-2045(22)00224-8. PMID: 35576956
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J, Califano R, Nishio M, Orlandi F, Alatorre-Alexander J, Leal T, Cheng Y, Lee JS, Lam S, McCleland M, Deng Y, Phan S, Horn L
J Clin Oncol 2021 Feb 20;39(6):619-630. Epub 2021 Jan 13 doi: 10.1200/JCO.20.01055. PMID: 33439693Free PMC Article
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR; KEYNOTE-604 Investigators
J Clin Oncol 2020 Jul 20;38(21):2369-2379. Epub 2020 May 29 doi: 10.1200/JCO.20.00793. PMID: 32468956Free PMC Article
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators
Lancet 2019 Nov 23;394(10212):1929-1939. Epub 2019 Oct 4 doi: 10.1016/S0140-6736(19)32222-6. PMID: 31590988

Prognosis

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group
Lancet Oncol 2022 Jun;23(6):739-747. Epub 2022 May 13 doi: 10.1016/S1470-2045(22)00224-8. PMID: 35576956
Durvalumab: A Review in Extensive-Stage SCLC.
Al-Salama ZT
Target Oncol 2021 Nov;16(6):857-864. Epub 2021 Nov 3 doi: 10.1007/s11523-021-00843-0. PMID: 34731446Free PMC Article
Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer.
Rittberg R, Banerji S, Kim JO, Rathod S, Dawe DE
Am J Clin Oncol 2021 Dec 1;44(12):629-638. doi: 10.1097/COC.0000000000000867. PMID: 34628433
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators
Lancet 2019 Nov 23;394(10212):1929-1939. Epub 2019 Oct 4 doi: 10.1016/S0140-6736(19)32222-6. PMID: 31590988
Advances in antibody therapeutics targeting small-cell lung cancer.
Lu H, Jiang Z
Adv Clin Exp Med 2018 Sep;27(9):1317-1323. doi: 10.17219/acem/70159. PMID: 29790694

Clinical prediction guides

Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Bria E, Morgillo F, Garassino MC, Ciardiello F, Ardizzoni A, Stefani A, Verderame F, Morabito A, Chella A, Tonini G, Gilli M, Del Signore E, Berardi R, Mencoboni M, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Pazzola A, Iero M, De Marinis F
Oncologist 2024 May 3;29(5):e690-e698. doi: 10.1093/oncolo/oyad342. PMID: 38377176Free PMC Article
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV
J Thorac Oncol 2022 Sep;17(9):1122-1129. Epub 2022 Jun 25 doi: 10.1016/j.jtho.2022.05.016. PMID: 35764236
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Liu C, Liao J, Wu X, Zhao X, Sun S, Wang H, Hu Z, Zhang Y, Yu H, Wang J
Thorac Cancer 2022 May;13(10):1463-1470. Epub 2022 Apr 7 doi: 10.1111/1759-7714.14414. PMID: 35388976Free PMC Article
Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer.
Rittberg R, Banerji S, Kim JO, Rathod S, Dawe DE
Am J Clin Oncol 2021 Dec 1;44(12):629-638. doi: 10.1097/COC.0000000000000867. PMID: 34628433
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Ohnishi T, Sagara H
Curr Oncol 2021 Feb 27;28(2):1094-1113. doi: 10.3390/curroncol28020106. PMID: 33673470Free PMC Article

Recent systematic reviews

The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
Wang BC, Fu C, Lin GH
Front Immunol 2023;14:1185577. Epub 2023 May 5 doi: 10.3389/fimmu.2023.1185577. PMID: 37215120Free PMC Article
Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis.
Sathiyapalan A, Febbraro M, Pond GR, Ellis PM
Curr Oncol 2022 Nov 22;29(12):9046-9065. doi: 10.3390/curroncol29120709. PMID: 36547123Free PMC Article
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Ohnishi T, Sagara H
Curr Oncol 2021 Feb 27;28(2):1094-1113. doi: 10.3390/curroncol28020106. PMID: 33673470Free PMC Article
Irinotecan compared with etoposide in combination with platinum in previously untreated extensive stage small cell lung cancer: An updated systemic review.
Hu Q, Wang Q, Zhu H, Yao Y, Song Q
J Cancer Res Ther 2016 Apr-Jun;12(2):881-7. doi: 10.4103/0973-1482.138002. PMID: 27461668
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
Behera M, Pillai RN, Owonikoko TK, Kim S, Steuer C, Chen Z, Saba NF, Belani CP, Khuri FR, Ramalingam SS
J Thorac Oncol 2015 Aug;10(8):1142-7. doi: 10.1097/JTO.0000000000000572. PMID: 26200267

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...